Researchers use several specific cell lines (i.e., SH-SY5Y, iPSCs, BV-2 microglial cells) in laboratory studies to model the AD pathology, test potential treatments, and investigate the role of amyloid beta plaques, tau protein abnormalities, and other key features of AD in a controlled environment. This evidence concerns the gene MAPT and Alzheimer disease.